Skip to main content
SpringerLink
Log in

Interleukin-2 for Nonmelanoma Skin Cancer

  • Chapter
Non-Surgical Treatment of Keratinocyte Skin Cancer

  • 592 Accesses

Surgery is the most frequent approach to treat Non-melanoma skin cancer (NMSC), but newer noninvasive treatment options such as immunotherapy with intralesional or perile-sional interleukin-2 (IL-2) have already proven efficacy. Intratumoral local IL-2 therapy leads to higher IL-2 concentrations at the tumor site and has fewer systemic side-effects compared to systemic IL-2 treatment. Local IL-2 treatment of the primary malignant lesion may result in regression of both the primary tumor and metastases. Immune-modulating agents such as IL-2 may be used in instances when other methods are difficult to perform or where cosmetic results are important. Additionally IL-2 may be a candidate for a combination therapy with standard and experimental NMSC treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts and figures. Atlanta, 2002

    Google Scholar 

  2. Reifenberger J, Ruzicka T. Basalzellkarzinom. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Landthaler M (eds) Dermatologie und Venerologie, 5. Auflage. Berlin/ Heidelberg, Germany/New York: Springer, 2005, pp. 1250–59

    Chapter  Google Scholar 

  3. Sterry W, Stockfleth E. Maligne epitheliale Tumoren. In Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Landthaler M (eds) Dermatologie und Venerologie, 5. Auflage. Berlin/Heidelberg, Germany/New York: Springer, 2005, pp. 1260–85

    Chapter  Google Scholar 

  4. Marcil I, Stern RS. Risk of developing a subsequent non-melanoma skin cancer in patients with a history of nonmela-noma skin cancer — a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524–30

    Article  CAS  PubMed  Google Scholar 

  5. Goldman GD. Squamous cell cancer: a practical approach. Semin Cutan Med Surg. 1998;17:80–95

    Article  CAS  PubMed  Google Scholar 

  6. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal-rransplants. Arch Dermatol. 1986;122:1288–93

    Article  CAS  PubMed  Google Scholar 

  7. Euvrard S, Kanitakis J, Pouteilnoble C, Dureau G, Touraine JL, Faure M, Claudy A, Thivolet J. Comparative epidemiologic-study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart-transplantation. J Am Acad Dermatol. 1995;33:222–29

    Article  CAS  PubMed  Google Scholar 

  8. Harwood AR, Osoba D, Hofstader SL, Goldstein MB, Cardella CJ, Holecek MJ, Kunynetz R, Giammarco RA. Kaposis sarcoma in recipients of renal-transplants. Am J Med. 1979;67:759–65

    Article  CAS  PubMed  Google Scholar 

  9. Smith KJ, Skelton HG, Yeager J, Angritt P, Wagner KF. Cutaneous neoplasms in a military population of HIV-1-positive patients. J Am Acad Dermatol. 1993;29:400–6

    Article  CAS  PubMed  Google Scholar 

  10. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, Biggar RJ, Zhuang ZP. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 1997;336:988–93

    Article  CAS  PubMed  Google Scholar 

  11. Curson C, Weedon D. Spontaneous Regression in Basal-Cell Carcinomas. J Cutan Pathol. 1979;6:432–7

    Article  CAS  PubMed  Google Scholar 

  12. Haeffner AC, Zepter K, Elmets CA, Wood GS. Analysis of tumor-infiltrating lymphocytes in cutaneous squamous cell carcinoma. Arch Dermatol. 1997;133:585–90

    Article  CAS  PubMed  Google Scholar 

  13. Smolle J, Wolf P. Is favorable prognosis of squamous cell carcinoma of the skin due to efficient immune surveillance? Arch Dermatol. 1997;133:645–6

    Article  CAS  PubMed  Google Scholar 

  14. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RSC. Regression in basal-cell carcinoma — an immunohistochemi-cal analysis. Br J Dermatol. 1994;130:1–8

    Article  CAS  PubMed  Google Scholar 

  15. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000;42:S18–22

    Article  Google Scholar 

  16. Wong DA, Bishop GA, Lowes MA, Cooke B, Barnetson RS, Halliday GM. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol. 2000;143:91–8

    Article  CAS  PubMed  Google Scholar 

  17. Kooy AJW, Prens EP, Van Heukelum A, Vuzevski VD, Van Joost T, Tank B. Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10. J Pathol. 1999;187:351–7

    Article  CAS  PubMed  Google Scholar 

  18. Kim J, Modlin RL, Moy RL, Dubinett SM, Mchugh T, Nickoloff BJ, Uyemura K. Il-10 production in cutaneous basal and squamous-cell carcinomas — a mechanism for evading the local T-cell immune-response. J Immunol. 1995;155:2240–7

    CAS  PubMed  Google Scholar 

  19. Nestle FO, Burg G, Fah J, WroneSmith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 1997;150:641–51

    CAS  PubMed  Google Scholar 

  20. Klein E. Immunotherapeutic approaches to skin cancer. Hosp Pract. 1976;11:107–16

    CAS  PubMed  Google Scholar 

  21. Holtermann OA, Papermaster B, Rosner D, Milgrom H, Klein E. Regression of cutaneous neoplasms following delayed-type hypersensitivity challenge reactions to micro-bial antigens or lymphokines. J Med. 1975;6:157–68

    CAS  PubMed  Google Scholar 

  22. Di Carlo E, Meazza R, Basso S, Rosso O, Comes A, Gaggero A, Musiani P, Santi L, Ferrini S. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice. J Pathol. 2000; 191:193–201

    Article  PubMed  Google Scholar 

  23. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2 — implicating macrophages without T-cells or natural-killer-cells in tumor rejection. Int J Cancer. 1995;61:253–60

    Article  CAS  PubMed  Google Scholar 

  24. Olejniczak K, Kasprzak A. Biological properties of interleu-kin 2 and its role in pathogenesis of selected diseases — a review. Med Sci Monit. 2008;14:RA179–89

    CAS  PubMed  Google Scholar 

  25. Maas RA, Dullens HFJ, Henk D, Vanweering J, Demik HJI, Koten JW, Belger RJ, Denotter W. Histological analysis of IL-2 induced regression of murine solid Sl2-tumors. Biotherapy. 1993;6:83–91

    Article  CAS  PubMed  Google Scholar 

  26. Sakkoula E, PipiliSynetosE,Maragoudakis ME.Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br J Pharmacol. 1997;122:793–5

    Article  CAS  PubMed  Google Scholar 

  27. Rafi AQ, Zeytun A, Bradley MJ, Sponenberg DP, Grayson RL, Nagarkatti M, Nagarkatti PS. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunol. 1998;161:3077–86

    CAS  PubMed  Google Scholar 

  28. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002; 105:570–5

    Article  CAS  PubMed  Google Scholar 

  29. Hammondmckibben DM, Seth A, Nagarkatti PS, Nagarkatti M. Characterization of factors regulating successful immuno-therapy using a tumor-specific cytotoxic T-Lymphocyte clone — role of interleukin-2, cycling pattern of lytic activity and adhesion molecules. Int J Cancer. 1995;60:828–36

    Article  CAS  Google Scholar 

  30. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8:1369–75

    Article  CAS  PubMed  Google Scholar 

  31. Ibe S, Qin ZH, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med. 2001;194:1549–59

    Article  CAS  PubMed  Google Scholar 

  32. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J. IL-2 regulates FOXP3 expression in human CD4(+) CD25(+) regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571–9

    Article  CAS  PubMed  Google Scholar 

  33. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595–601

    Article  CAS  PubMed  Google Scholar 

  34. Ahmadzadeh M, Rosenberg ST. IL-2 administration increases CD4(+)CD25(hi) Foxp3(+) regulatory T cells in cancer patients. Blood. 2006;107:2409–14

    Article  CAS  PubMed  Google Scholar 

  35. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4(+)CD25(+) regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–77

    Article  CAS  PubMed  Google Scholar 

  36. Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, Macfarlane MP, White RL, Steinberg SM, White DE, Einhorn JH, Seipp CA, Austin HA, Rosenberg SA, Schwartzentruber DJ. Renal dysfunction associated with the administration of high-dose Interleukin-2 in 199 consecutive patients with metastatic melanoma or renal-carcinoma. J Clin Oncol. 1994;12:2714–22

    CAS  PubMed  Google Scholar 

  37. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797–805

    Article  CAS  PubMed  Google Scholar 

  38. Philip T, Mercatello A, Negrier S, Philip I, Rebattu P, Kaemmerlin P, Gaspard M, Tognier E, Combaret V, Bijmann JT, Franks CR, Chauvin F, Moskovtchenko JF, Favrot M, Clavel M. Interleukin-2 with and without Lak cells in metastatic renal-cell carcinoma — the Lyon 1st-year experience in 20 patients. Cancer Treat Rev. 1989;16:91–104

    Article  PubMed  Google Scholar 

  39. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology. 1997;37:117–32

    Article  CAS  PubMed  Google Scholar 

  40. RosensteinM,EttinghausenSE,RosenbergSA.Extravasation of intravascular fluid mediated by the systemic administration of recombinant Interleukin-2. J Immunol. 1986;137: 1735–42

    CAS  PubMed  Google Scholar 

  41. Den Otter W, Balemans L, Battermann JJ, Bernsen MR, Cadee JA, Dobrowolski Z, Everse LA, Fiszer-Maliszewska L, Gavhumende R, De Groot JW, De Groot K, Hennink WE, Hill FWG, Jurgenliemp-Schulz I, Klein WR, Koten JW, Maas RA, Steerenberg P, Stewart R, Zembala M. Local low-dose IL-2 therapy. Hepato-gastroenterology. 1999;46: 1280–6

    CAS  Google Scholar 

  42. Fiszer-Maliszewska L, Den Otter W, Mordarski M. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength. Cancer Immunol Immunother. 1999;47:307–14

    Article  CAS  PubMed  Google Scholar 

  43. Mihara M, Nakayama H, Nakamura K, Morimura T, Hagari Y, Shimao S: Histologic-changes in superficial basal-cell epi-thelioma and Bowens disease by intralesional injection of recombinant Interleukin-2 — recombinant Interleukin-2 may induce redifferentiation of malignant-tumor cells invivo. Arch Dermatol. 1990;126:1107

    Article  CAS  PubMed  Google Scholar 

  44. Kaplan B, Moy RL. Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg. 2000; 26:1037–40

    Article  CAS  PubMed  Google Scholar 

  45. Urosevic M, Dummer R. Immunotherapy for nonmelanoma skin cancer — does it have a future? Cancer. 2002;94:477–85

    Article  CAS  PubMed  Google Scholar 

  46. 46.Dummer R, Rochlitz C, Velu T, Acres B, Limacher JM, Bleuzen P, Lacoste G, Slos P, Romero P, Urosevic M. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008;16:985–94

    Article  CAS  PubMed  Google Scholar 

  47. Dummer R, Becker JC, Boser B, Hartmann AA, Burg G. Successful therapy of metastatic eccrine poroma using per-ilesional interferon-alfa and Interleukin-2. Arch Dermatol. 1992;128:1127–8

    Article  CAS  PubMed  Google Scholar 

  48. Ghyka G, Alecu M, Halalau F, Coman G: Intralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma. Dermatol 1992;19:35–9

    CAS  PubMed  Google Scholar 

  49. Shibagaki R, Kishimoto S, Takenaka H, Yasuno H. Recombinant interleukin 2 monotherapy for classic Kaposi sarcoma. Arch Dermatol. 1998;134:1193–6

    Article  CAS  PubMed  Google Scholar 

  50. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA. Prolonged administration of low-dose Interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood. 1995;86: 3287–94

    CAS  PubMed  Google Scholar 

  51. Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest. 1998;101:1373–8

    Article  CAS  PubMed  Google Scholar 

  52. Nagatani T, Kin ST, Baba N, Miyamoto H, Nakajima H, Katoh Y. A case of cutaneous T-cell lymphoma treated with recombinant Interleukin-2 (Ril-2). Acta Derm-Venereol. 1988;68:504–8

    CAS  PubMed  Google Scholar 

  53. Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, Kuzel TM. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome. J Am Acad Dermatol. 2007;56:580–3

    Article  PubMed  Google Scholar 

  54. RosensteinM,EttinghausenSE,RosenbergSA.Extravasation of intravascular fluid mediated by the systemic administration of recombinant Interleukin-2. J Immunol. 1986;137: 1735–42

    CAS  PubMed  Google Scholar 

  55. Jacobs JJ, Sparendam D, Den Otter W. Local interleukin 2 therapy is most effective against cancer when injected intra-tumourally. Cancer Immunol Immunother. 2005;54:647–54

    Article  CAS  PubMed  Google Scholar 

  56. Samlowski WE, McGregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. ReGel (R) polymer-based delivery of interleukin-2 as a cancer treatment. J Immunother. 2006; 29:524–35

    Article  CAS  PubMed  Google Scholar 

  57. Hofbauer GFL, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008; 18:104–11

    Article  CAS  PubMed  Google Scholar 

  58. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/ DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol. 1999;17:3313–23

    CAS  PubMed  Google Scholar 

  59. Horton HM, Lalor PA, Rolland AP. IL-2 plasmid electropo-ration: from preclinical studies to phase I clinical trial. Methods Mol Biol. 2008;423:361–72

    Article  CAS  PubMed  Google Scholar 

  60. Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM, Koten JW. Local therapy of cancer with free IL-2. Cancer Immunol Immunother. 2008;57:931–50

    Article  CAS  Google Scholar 

  61. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional inter-leukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol. 2007;156:337–45

    Article  CAS  PubMed  Google Scholar 

  62. Van Es RJJ, Baselmans AHC, Koten JW, Van Dijk JE, Koole R, Den Otter W. Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity. Anticancer Res. 2000;20:4163–70

    CAS  Google Scholar 

  63. Enk AH, Nashan D, Rubben A, Knop J. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer. 2000;88:2042–6

    Article  CAS  PubMed  Google Scholar 

  64. Bendiksen S, Rekvig OP. Interleukin-2, but not interleu-kin-15, is required to terminate experimentally induced clonal T-cell anergy. Scand J Immunol. 2004;60:64–73

    Article  CAS  PubMed  Google Scholar 

  65. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000;27:194–203

    CAS  PubMed  Google Scholar 

  66. Kubo T, Hatton RD, Oliver J, Liu XF, Elson CO, Weaver CT. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol. 2004;173: 7249–58

    CAS  PubMed  Google Scholar 

  67. Tomova R, Pomakov J, Jacobs JJL, Adjarov D, Popova S, Altankova I, Den Otter W, Krastev Z. Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res. 2006;26:2037–47

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CLINIC DUFOUR 31, Dufourstrasse 31, Zürich, 8008, Switzerland

    Arpad Farkas

Authors
  1. Arpad Farkas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arpad Farkas .

Editor information

Editors and Affiliations

  1. Dept. of Dermatology, University of Copenhagen, Roskilde Hospital, Køgevej 7-13, Roskilde, 4000, Denmark

    Gregor B. E. Jemec

  2. Dept. Dermatology & Allergology, University of Szeged, Korányi Fasor 6, Szeged, 6720, Hungary

    Lajos Kemeny

  3. Dept. Dermatology, Marshfield Clinic, 1000 N. Oak Ave., Marshfield, WI, 54449, USA

    Donald Miech

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Farkas, A. (2010). Interleukin-2 for Nonmelanoma Skin Cancer. In: Jemec, G.B.E., Kemeny, L., Miech, D. (eds) Non-Surgical Treatment of Keratinocyte Skin Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79341-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79341-0_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79340-3

  • Online ISBN: 978-3-540-79341-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation